DCCD inhibits sarcoplasmic reticulum (Ca2+)ATPase by reacting with the Ca2+-binding site located in a hydrophobic region of the enzyme.
Answers are grounded in this paper and cite their sources.
DCCD site mapping on SR ATPase is hypothesis-generating; leaves open any role in cardiac Ca2+ handling or therapy.
Dicyclohexylcarbodiimide (DCCD) inhibits the (Ca2+)ATPase, Ca2+ uptake by sarcoplasmic reticulum vesicles and Ca2+ binding to the (Ca2+)ATPase from sarcoplasmic reticulum. Ca2+ (at micron concentrations) specifically protects against DCCD inhibition. The inhibition can, therefore, be readily demonstrated only in the presence of Ca2+ chelating agents such as EGTA. In the presence of EGTA, the ionophore A-23187 increased the sensitivity to DCCD. The ionophore also increased the phosphorylation of the enzyme by inorganic phosphate in the presence of Mg2+. These results indicate that tightly bound Ca2+ is located in a hydrophobic region of the enzyme which is not accessible to EGTA. Complete inhibition of the (Ca2+)ATPase is accompanied by binding of 4--5 nmol of [14C]DCCD per mg of ATPase protein in the absence of Ca2+ compared with 2 nmol bound per mg in the presence of Ca2+ with no ATPase inhibition. Assuming a molecular weight of 100 000 for the ATPase monomer, about 1 nmol of DCCD inhibits 4 nmol of ATPase. This result suggests that the minimal functional unit of the enzyme is a tetramer. Following trypsin digestion of the [14C]DCCD-labeled ATPase most of the radioactivity appears in the 20 000-dalton fragment. We propose that DCCD reacts with the Ca2+-binding site of the ATPase.
No takes yet. Share an insight, caveat, or question.
Pick et al. (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: